Linagliptin in type 2 diabetes mellitus: glycemic control and beyond
DOI:
https://doi.org/10.18203/2320-6012.ijrms20260995Keywords:
Linagliptin, Type 2 diabetes mellitus, DPP-4 inhibitor, SGLT2 inhibitor, Glycemic control, Cardio-vascular safety, Renal safety, Combination therapyAbstract
Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder requiring comprehensive strategies to achieve sustained glycemic control and reduce complications. Linagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i), provides effective glycemic control with a low risk of hypoglycaemia and weight neutrality. Its once-daily dosing without the need for renal or hepatic dose adjustment makes it suitable for patients with multiple comorbidities. Large clinical trials, including CARMELINA and CAROLINA, have established its cardiovascular and renal safety. Beyond monotherapy, combination therapy with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor (SGLT2i), demonstrates synergistic benefits. This combination improves glycemic parameters, supports weight reduction, and enhances cardiorenal outcomes. Phase III trials show that fixed-dose combinations of dapagliflozin and linagliptin achieve superior HbA1c reduction and improved postprandial glucose control compared with monotherapy, with favourable safety and tolerability.
Metrics
References
He KJ, Wang H, Xu J, Gong G, Liu X, Guan H. Global burden of type 2 diabetes mellitus from 1990 to 2021, with projections of prevalence to 2044: a systematic analysis across SDI levels for the global burden of disease study 2021. Front Endocrinol. 2024;15:1501690. DOI: https://doi.org/10.3389/fendo.2024.1501690
Banday MZ, Sameer AS, Nissar S. Pathophysiology of diabetes: An overview. Avicenna J Med. 2020; 10:174-88. DOI: https://doi.org/10.4103/ajm.ajm_53_20
Ye J, Wu Y, Yang S, Zhu D, Chen F, Chen J, et al. The global, regional and national burden of type 2 diabetes mellitus in the past, present and future: a systematic analysis of the Global Burden of Disease Study 2019. Front Endocrinol. 2023;14. Available at: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1192629/full. Accessed on 28 December 2025. DOI: https://doi.org/10.3389/fendo.2023.1192629
Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes - Endotext - NCBI Bookshelf. 2025. Available at: https://www.ncbi.nlm.nih.gov/books/NBK279141/. Accessed on 28 December 2025.
Chavan OR, Jakune VL, Sable VU. Revolutionizing Type 2 Diabetes Management: A Pharmacological Perspective. Int J Res Publ Rev. 2024;5:2320-5.
Freeman MK. Efficacy and Safety of Linagliptin (Tradjenta) in Adults With Type-2 Diabetes Mellitus. Pharm Ther. 2011;36:807-42.
Kasina SVSK, Baradhi KM. Dipeptidyl Peptidase IV (DPP IV) Inhibitors. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2025. Available at: http://www.ncbi.nlm.nih.gov/books/NBK542331/. Accessed on 28 December 2025.
Saini K, Sharma S, Khan Y. DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature. Front Mol Biosci. 2023;10: 1130625. Available at: https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2023.1130625/full. Accessed on 28 December 2025. DOI: https://doi.org/10.3389/fmolb.2023.1130625
Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13:258-67. DOI: https://doi.org/10.1111/j.1463-1326.2010.01350.x
Xie X, Wu C, Hao Y, Wang T, Yang Y, Cai P, et al. Benefits and risks of drug combination therapy for diabetes mellitus and its complications: a comprehensive review. Front Endocrinol. 2023; 14:1301093. DOI: https://doi.org/10.3389/fendo.2023.1301093
Kalra S, Bhattacharya S, Dhingra A, Das S, Kapoor N, Shaikh S, et al. Expert Consensus on Dipeptidyl Peptidase-4 Inhibitor-Based Therapies in the Modern Era of Type 2 Diabetes Mellitus Management in India. Cureus. 2025;16:e61766. DOI: https://doi.org/10.7759/cureus.61766
Chadha M, Das AK, Deb P, Gangopadhyay KK, Joshi S, Kesavadev J, et al. Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting. Diabetes Ther. 2022;13:1097-114. DOI: https://doi.org/10.1007/s13300-022-01219-x
Drugs Controller General of India (DCG(I). Fixed dose combinations approved by DCG(I). Available at:https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdfdocuments/fixed_dose_combinations_2024.pdf. Accessed on 28 December 2025.
Park JW, Kim JM, Noh JH, Kim KA, Chung H, Kim E, et al. Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans. Research Gate. 2022; 14:591. DOI: https://doi.org/10.3390/pharmaceutics14030591
Ito T, Naito Y, Shimmoto N, Ochiai K, Hayashi N, Okamura T. Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance. Expert Opin Drug Saf. 2021; 20(4):363-72. DOI: https://doi.org/10.1080/14740338.2021.1859477
Hoogwerf BJ, MacKenzie M, Sealls W, Cordova J, Gandhi P. Real-World Glycemic Lowering Effectiveness of Linagliptin Among Adults with Type 2 Diabetes by Age, Renal Function, and Race. Diabetes Ther. 2020;11:1527-36. DOI: https://doi.org/10.1007/s13300-020-00841-x
Han SY, Yoon SA, Han BG, Kim SG, Jo Y, Jeong KH, et al. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40‐week extension of the GUARD randomized study. Diabetes Obes Metab. 2018;20(2):292-300. DOI: https://doi.org/10.1111/dom.13059
Parthan G, Bhansali S, Kurpad AV, Walia R, Bhat K, Bhansali A. Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial. BMC Pharmacol Toxicol. 2018;19:38. DOI: https://doi.org/10.1186/s40360-018-0228-z
Lajara R, Aguilar R, Hehnke U, Woerle HJ, Eynatten M von. Efficacy and Safety of Linagliptin in Subjects With Long-standing Type 2 Diabetes Mellitus (>10 Years): Evidence From Pooled Data of Randomized, Double-blind, Placebo-controlled, Phase III Trials. Clin Ther. 2014;36(11):1595-605. DOI: https://doi.org/10.1016/j.clinthera.2014.07.020
Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, et al. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. Diabetes Obes Metab. 2012;14(12):1145-54. DOI: https://doi.org/10.1111/dom.12011
Kawamori R, Inagaki N, Araki E, Watada H, Hayashi N, Horie Y, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab. 2012;14(4):348-57. DOI: https://doi.org/10.1111/j.1463-1326.2011.01545.x
Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Herbach K, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med. 2010;27(12):1409-19. DOI: https://doi.org/10.1111/j.1464-5491.2010.03131.x
Ross SA, Rafeiro E, Meinicke T, Toorawa R, Weber-Born S, Woerle HJ. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Curr Med Res Opin. 2012;28(9):1465-74. DOI: https://doi.org/10.1185/03007995.2012.714360
Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69-79. DOI: https://doi.org/10.1001/jama.2018.18269
Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155-66. DOI: https://doi.org/10.1001/jama.2019.13772
Cioffi G, Giorda CB, Lucci D, Nada E, Ognibeni F, Mancusi C, et al. Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial. Eur J Prev Cardiol. 2021; 28(1):8-17. DOI: https://doi.org/10.1177/2047487320939217
De Boer SA, Heerspink HJL, Juárez Orozco LE, van Roon AM, Kamphuisen PW, Smit AJ, et al. Effect of linagliptin on pulse wave velocity in early type 2 diabetes: A randomized, double-blind, controlled 26-week trial (RELEASE). Diabetes Obes Metab. 2017; 19(9):1147-54. DOI: https://doi.org/10.1111/dom.12925
Cooper ME, Rosenstock J, Kadowaki T, Seino Y, Wanner C, Schnaidt S, et al. Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo‐controlled CARMELINA® trial. Diabetes Obes Metab. 2020;22(6):1062-73. DOI: https://doi.org/10.1111/dom.13995
Perkovic V, Toto R, Cooper ME, Mann JFE, Rosenstock J, McGuire DK, et al. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. Diabetes Care. 2020;43(8):1803-12. DOI: https://doi.org/10.2337/dc20-0279
McGill JB, Sloan L, Newman J, Patel S, Sauce C, von Eynatten M, et al. Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment. Diabetes Care. 2013; 36(8):237-44. DOI: https://doi.org/10.2337/dc12-0706
Yagoglu AI, Dizdar OS, Erdem S, Akcakaya B, Gunal AI. The effect of linagliptin on renal progression in type-2 diabetes mellitus patients with chronic kidney disease: A prospective randomized controlled study. Nefrol Engl Ed. 2020;40(6):664-71. DOI: https://doi.org/10.1016/j.nefro.2020.04.023
American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(1): S181-206.
Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update. Endocr Pract. 2023; 29(3):305-40. DOI: https://doi.org/10.1016/j.eprac.2023.02.001
Chawla R, Madhu SV, Makkar BM, Ghosh S, Saboo B, Kalra S. RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. Indian J Endocrinol Metab. 2020; 24(1):1-122. DOI: https://doi.org/10.4103/ijem.IJEM_225_20
Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44:4043-140. DOI: https://doi.org/10.1093/eurheartj/ehad774
Yu C, Yang H, Zhang B, Chen S, Yang S, Li F, et al. Evaluating the effects of liraglutide, empagliflozin and linagliptin on mild cognitive impairment remission in patients with type 2 diabetes (LIGHT-MCI): study protocol for a multicentre, randomised controlled trial with an extension phase. BMJ Open. 2025;15:e095382. DOI: https://doi.org/10.1136/bmjopen-2024-095382
Turchin A. BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes. clinicaltrials.gov; 2023. Available at: https://clinicaltrials.gov/study/NCT05161429. Accessed on 28 December 2025. DOI: https://doi.org/10.25302/01.2026.DB.2020C220308
Kaiser Permanente. Comparison of Type 2 Diabetes Pharmacotherapy Regimens Using Targeted Learning. clinicaltrials.gov. 2024. Available at: https://clinicaltrials.gov/study/NCT05073692. Accessed on 28 December 2025.
CTRI-A. Multicentric, Prospective, Active Controlled, Parallel Group, Randomized, Double Blind, Comparative, Phase III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Combination of Linagliptin, Glimepiride and Metformin Hydrochloride Extended-Release Tablets Versus Fixed Dose Combination of Glimepiride and Metformin Hydrochloride Sustained Release Tablets in Patients with Type 2 Diabetes Mellitus. 2025. Available at: https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=OTc2Njk=&Enc=&userName=linagliptin. Accessed on 28 December 2025.
CTRI-Role of Linagliptin and Dapagliflozin versus Vildagliptin and Dapagliflozin in Diabetes patients. 2025. Available at: https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=OTgwNzA=&Enc=&userName=linagliptin. Accessed on 28 December 2025.
CTRI-A Real-World Study in India to Comparison of Vildagliptin Twice Daily Vs Vildagliptin Once Daily Sitagliptin Once Daily and Linagliptin Once Daily Therapy using Continuous Glucose Monitoring in Type 2 Diabetes Mellitus Patients Uncontrolled on Metformin. 2025. Available at: https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=MTEwNTY3&Enc=&userName=linagliptin. Accessed on 28 December 2025.
Downloads
Published
How to Cite
Issue
Section
